| Literature DB >> 25829087 |
Sree Harsha Tirumani1, Ann S LaCasce2, Heather A Jacene3.
Abstract
The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.Entities:
Keywords: Diffuse large B-cell lymphoma; FDG-PET/CT; Hodgkin lymphoma; Interim PET/CT; Lymphoma
Mesh：
Substances：
Year: 2015 PMID： 25829087 DOI： 10.1016/j.cpet.2014.12.005
Source DB: PubMed Journal: PET Clin ISSN： 1556-8598